“Definium's stock more than doubled following strong Phase 3 results for its LSD-based major depressive disorder therapy, which exhibited durable treatment effects and high remission rates. This clinical milestone has significantly de-risked the development pipeline ahead of its upcoming generalized anxiety disorder readout.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.